Charlotte's Web Holdings announced its Q2 2026 financial results, showing a 15.2% revenue decline to $10.9 million due to retail channel restructuring but improved gross margin to 47.5%. The company completed a major recapitalization, eliminating $57 million in liabilities and strengthening its balance sheet with $14 million in cash. Significant federal hemp policy developments include bipartisan legislation to protect full-spectrum hemp products and a Senate decision to delay a federal hemp product ban, supporting Charlotte's Web's market position. The company is also advancing its botanical drug candidate DeFloria and transitioning to in-house gummy production to improve margins further. Management expects continued cost improvements and supports ongoing federal regulatory reforms.
